Open-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease.
Latest Information Update: 15 Jan 2020
At a glance
- Drugs Sumanirole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 15 Jan 2020 New trial record